Pharmaceutical Information |
Drug Name |
Saquinavir mesylate |
Drug ID |
BADD_D01989 |
Description |
Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies.[A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] |
Indications and Usage |
For the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues. |
Marketing Status |
Discontinued; Prescription |
ATC Code |
J05AE01 |
DrugBank ID |
DB01232
|
KEGG ID |
D01160
|
MeSH ID |
D019258
|
PubChem ID |
60934
|
TTD Drug ID |
D0WI3T
|
NDC Product Code |
0004-0244 |
Synonyms |
Saquinavir | Saquinivir | Ro 31-8959 | Ro 31 8959 | Ro 318959 | Saquinavir Monomethanesulfonate | Monomethanesulfonate, Saquinavir | Saquinavir Mesylate | Invirase |
|
Chemical Information |
Molecular Formula |
C39H54N6O8S |
CAS Registry Number |
149845-06-7 |
SMILES |
CC(C)(C)NC(=O)C1CC2CCCCC2CN1CC(C(CC3=CC=CC=C3)NC(=O)C(CC(=O)N)NC(=O)C4=NC5=CC=CC
=C5C=C4)O.CS(=O)(=O)O |
Chemical Structure |
|
|
ADR Related Proteins Induced by Drug |
ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
Not Available | Not Available | Not Available | Not Available | Not Available |
|
ADRs Induced by Drug |
|